In re Gentiva Securities Litigation
Case Number:
2:10-cv-05064
Court:
Nature of Suit:
Multi Party Litigation:
Class Action
Judge:
Firms
Companies
Sectors & Industries:
-
April 03, 2015
Gentiva Pays $6.5M To Exit Investors' Fraud Action
Home care company Gentiva Health Services Inc. agreed on Friday to pay $6.5 million to settle a proposed investor class action accusing its executives of inflating Gentiva stock prices by overbilling Medicare, more than a year after a New York federal judge dismissed all but one defendant.
-
October 04, 2013
Gentiva Looks To Quash Investors' Fraud Action
Home care company Gentiva Health Services Inc. told a New York federal judge Thursday that it and two of its executives should be let go from a proposed class action accusing them of inflating its stock price by overbilling Medicare.
-
September 19, 2013
Judge Drops 2 Gentiva Execs From Securities Class Action
A New York federal judge on Thursday dropped two Gentiva Health Services Inc. executives from a proposed securities fraud class action accusing the home health care company of inflating its stock price by overbilling Medicare, but allowed the case to proceed against two other executives and Gentiva itself.
-
March 26, 2013
Gentiva Beats Medicare Billing Fraud Securities Suit
A New York federal judge Monday wiped out a proposed securities fraud class action accusing home health care company Gentiva Health Services Inc. of inflating its stock price by overbilling Medicare, finding no evidence executives acted with ill intent by trying to boost profits.
-
November 30, 2012
SEC Won't Charge Gentiva Over Medicare Reimbursement
Gentiva Health Services Inc. said Thursday that the U.S. Securities and Exchange Commission wouldn't be bringing charges against the company over its participation in a Medicare reimbursement program for home health care, ending a more than two-year investigation.
-
June 18, 2012
Gentiva Says Investors Can't Back Up Medicare Fraud Claims
Gentiva Health Services Inc. said Friday that a consolidated class of shareholders had provided no evidence to support allegations that the nation's largest home health care provider misled investors about its financial health as lawmakers and regulators scrutinized the company's Medicare reimbursement practices.